Skip to main content
Erschienen in: Journal of Inherited Metabolic Disease 2/2018

06.11.2017 | Original Article

Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expression

verfasst von: Xing-Li Meng, Erland Arning, Mary Wight-Carter, Taniqua S. Day, Siamak Jabbarzadeh-Tabrizi, Shuyuan Chen, Robin J. Ziegler, Teodoro Bottiglieri, Jay W. Schneider, Seng H. Cheng, Raphael Schiffmann, Jin-Song Shen

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Fabry disease is a glycosphingolipidosis caused by deficient activity of α-galactosidase A; it is one of a few diseases that are associated with priapism, an abnormal prolonged erection of the penis. The goal of this study was to investigate the pathogenesis of Fabry disease-associated priapism in a mouse model of the disease. We found that Fabry mice develop late-onset priapism. Neuronal nitric oxide synthase (nNOS), which was predominantly present as the 120-kDa N-terminus-truncated form, was significantly upregulated in the penis of 18-month-old Fabry mice compared to wild type controls (~fivefold). Endothelial NOS (eNOS) was also upregulated (~twofold). NO level in penile tissues of Fabry mice was significantly higher than wild type controls at 18 months. Gene transfer-mediated enzyme replacement therapy reversed abnormal nNOS expression in the Fabry mouse penis. The penile nNOS level was restored by antiandrogen treatment, suggesting that hyperactive androgen receptor signaling in Fabry mice may contribute to nNOS upregulation. However, the phosphodiesterase-5A expression level and the adenosine content in the penis, which are known to play roles in the development of priapism in other etiologies, were unchanged in Fabry mice. In conclusion, these data suggested that increased nNOS (and probably eNOS) content and the consequential elevated NO production and high arterial blood flow in the penis may be the underlying mechanism of priapism in Fabry mice. Furthermore, in combination with previous findings, this study suggested that regulation of NOS expression is susceptible to α-galactosidase A deficiency, and this may represent a general pathogenic mechanism of Fabry vasculopathy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Backenroth R, Landau EH, Goren M, Raas-Rothschild A (2010) Fabry disease and G6PD in three family members with priapism: is the nitric oxide pathway to blame? J Sex Med 7:1588–1591CrossRefPubMed Backenroth R, Landau EH, Goren M, Raas-Rothschild A (2010) Fabry disease and G6PD in three family members with priapism: is the nitric oxide pathway to blame? J Sex Med 7:1588–1591CrossRefPubMed
Zurück zum Zitat Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL (2012) New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 9:79–87CrossRefPubMed Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL (2012) New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 9:79–87CrossRefPubMed
Zurück zum Zitat Bodary PF, Shen Y, Vargas FB et al (2005) Alpha-galactosidase a deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111:629–632CrossRefPubMed Bodary PF, Shen Y, Vargas FB et al (2005) Alpha-galactosidase a deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111:629–632CrossRefPubMed
Zurück zum Zitat Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 276:1163–1167CrossRefPubMed Brady R, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 276:1163–1167CrossRefPubMed
Zurück zum Zitat Burnett AL (2004) Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 16(Suppl 1):S15–S19CrossRefPubMed Burnett AL (2004) Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res 16(Suppl 1):S15–S19CrossRefPubMed
Zurück zum Zitat Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL (2005) Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A 102:1661–1666CrossRefPubMedPubMedCentral Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL (2005) Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A 102:1661–1666CrossRefPubMedPubMedCentral
Zurück zum Zitat Christodoulou J, Dewan PA, Tan HL, Rogers JG (1988) Priapism: a rare complication of Fabry's disease. Pediatr Surg Int 4:69–70CrossRef Christodoulou J, Dewan PA, Tan HL, Rogers JG (1988) Priapism: a rare complication of Fabry's disease. Pediatr Surg Int 4:69–70CrossRef
Zurück zum Zitat Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774 Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733–3774
Zurück zum Zitat Endres W, Shin YS, Rieth M, Block T, Schmiedt E, Knorr D (1987) Priapism in Fabry's disease during testosterone treatment. Klin Wochenschr 65:925CrossRefPubMed Endres W, Shin YS, Rieth M, Block T, Schmiedt E, Knorr D (1987) Priapism in Fabry's disease during testosterone treatment. Klin Wochenschr 65:925CrossRefPubMed
Zurück zum Zitat Foda MM, Mahmood K, Rasuli P, Dunlap H, Kiruluta G, Schillinger JF (1996) High-flow priapism associated with Fabry's disease in a child: a case report and review of the literature. Urology 48:949–952CrossRefPubMed Foda MM, Mahmood K, Rasuli P, Dunlap H, Kiruluta G, Schillinger JF (1996) High-flow priapism associated with Fabry's disease in a child: a case report and review of the literature. Urology 48:949–952CrossRefPubMed
Zurück zum Zitat Garcia-Consuegra J, Padron M, Jaureguizar E, Carrascosa C, Ramos J (1990) Priapism and Fabry disease: a case report. Eur J Pediatr 149:500–501CrossRefPubMed Garcia-Consuegra J, Padron M, Jaureguizar E, Carrascosa C, Ramos J (1990) Priapism and Fabry disease: a case report. Eur J Pediatr 149:500–501CrossRefPubMed
Zurück zum Zitat Gonzalez CM, Brannigan RE, Bervig T et al (2001) Protein and gene expression of nitric oxide synthase isoforms I and III in the rat penile shaft. J Androl 22:54–61PubMed Gonzalez CM, Brannigan RE, Bervig T et al (2001) Protein and gene expression of nitric oxide synthase isoforms I and III in the rat penile shaft. J Androl 22:54–61PubMed
Zurück zum Zitat Jung HC, Mun KH, Park TC et al (1997) Role of nitric oxide in penile erection. Yonsei Med J 38:261–269CrossRefPubMed Jung HC, Mun KH, Park TC et al (1997) Role of nitric oxide in penile erection. Yonsei Med J 38:261–269CrossRefPubMed
Zurück zum Zitat Kang JJ, Shu L, Park JL, Shayman JA, Bodary PF (2014) Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in alpha-galactosidase a. Am J Physiol Gastrointest Liver Physiol 306:G140–G146CrossRefPubMed Kang JJ, Shu L, Park JL, Shayman JA, Bodary PF (2014) Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in alpha-galactosidase a. Am J Physiol Gastrointest Liver Physiol 306:G140–G146CrossRefPubMed
Zurück zum Zitat Lagoda G, Sezen SF, Hurt KJ, Cabrini MR, Mohanty DK, Burnett AL (2014) Sustained nitric oxide (NO)-releasing compound reverses dysregulated NO signal transduction in priapism. FASEB J 28:76–84CrossRefPubMedPubMedCentral Lagoda G, Sezen SF, Hurt KJ, Cabrini MR, Mohanty DK, Burnett AL (2014) Sustained nitric oxide (NO)-releasing compound reverses dysregulated NO signal transduction in priapism. FASEB J 28:76–84CrossRefPubMedPubMedCentral
Zurück zum Zitat Mi T, Abbasi S, Zhang H et al (2008) Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 118:1491–1501CrossRefPubMedPubMedCentral Mi T, Abbasi S, Zhang H et al (2008) Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 118:1491–1501CrossRefPubMedPubMedCentral
Zurück zum Zitat Moore DF, Scott LT, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506–1512CrossRefPubMed Moore DF, Scott LT, Gladwin MT et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506–1512CrossRefPubMed
Zurück zum Zitat Ning C, Wen J, Zhang Y et al (2014) Excess adenosine A2B receptor signaling contributes to priapism through HIF-1alpha mediated reduction of PDE5 gene expression. FASEB J 28:2725–2735CrossRefPubMedPubMedCentral Ning C, Wen J, Zhang Y et al (2014) Excess adenosine A2B receptor signaling contributes to priapism through HIF-1alpha mediated reduction of PDE5 gene expression. FASEB J 28:2725–2735CrossRefPubMedPubMedCentral
Zurück zum Zitat Penson DF, Ng C, Cai L, Rajfer J, Gonzalez-Cadavid NF (1996) Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod 55:567–574CrossRefPubMed Penson DF, Ng C, Cai L, Rajfer J, Gonzalez-Cadavid NF (1996) Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod 55:567–574CrossRefPubMed
Zurück zum Zitat Puri V, Watanabe R, Dominguez M et al (1999) Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat Cell Biol 1:386–388CrossRefPubMed Puri V, Watanabe R, Dominguez M et al (1999) Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat Cell Biol 1:386–388CrossRefPubMed
Zurück zum Zitat Qu XW, Wang H, Rozenfeld RA, Huang W, Hsueh W (1999) Type I nitric oxide synthase (NOS) is the predominant NOS in rat small intestine. Regulation by platelet-activating factor. Biochim Biophys Acta 1451:211–217CrossRefPubMed Qu XW, Wang H, Rozenfeld RA, Huang W, Hsueh W (1999) Type I nitric oxide synthase (NOS) is the predominant NOS in rat small intestine. Regulation by platelet-activating factor. Biochim Biophys Acta 1451:211–217CrossRefPubMed
Zurück zum Zitat Reilly CM, Zamorano P, Stopper VS, Mills TM (1997) Androgenic regulation of NO availability in rat penile erection. J Androl 18:110–115PubMed Reilly CM, Zamorano P, Stopper VS, Mills TM (1997) Androgenic regulation of NO availability in rat penile erection. J Androl 18:110–115PubMed
Zurück zum Zitat Schirar A, Bonnefond C, Meusnier C, Devinoy E (1997) Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat. Endocrinology 138:3093–3102CrossRefPubMed Schirar A, Bonnefond C, Meusnier C, Devinoy E (1997) Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat. Endocrinology 138:3093–3102CrossRefPubMed
Zurück zum Zitat Shen JS, Arning E, West ML et al (2017) Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease. Hum Mol Genet 26:1182–1192CrossRefPubMed Shen JS, Arning E, West ML et al (2017) Tetrahydrobiopterin deficiency in the pathogenesis of Fabry disease. Hum Mol Genet 26:1182–1192CrossRefPubMed
Zurück zum Zitat Shen JS, Meng XL, Wight-Carter M et al (2015) Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice. Hum Mol Genet 24:3181–3191CrossRefPubMed Shen JS, Meng XL, Wight-Carter M et al (2015) Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice. Hum Mol Genet 24:3181–3191CrossRefPubMed
Zurück zum Zitat Toda N, Ayajiki K, Okamura T (2005) Nitric oxide and penile erectile function. Pharmacol Ther 106:233–266CrossRefPubMed Toda N, Ayajiki K, Okamura T (2005) Nitric oxide and penile erectile function. Pharmacol Ther 106:233–266CrossRefPubMed
Zurück zum Zitat Wang Y, Goligorsky MS, Lin M, Wilcox JN, Marsden PA (1997) A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase. J Biol Chem 272:11392–11401CrossRefPubMed Wang Y, Goligorsky MS, Lin M, Wilcox JN, Marsden PA (1997) A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase. J Biol Chem 272:11392–11401CrossRefPubMed
Zurück zum Zitat Ziegler RJ, Cherry M, Barbon CM et al (2007) Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase a. Mol Ther 15:492–500CrossRef Ziegler RJ, Cherry M, Barbon CM et al (2007) Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase a. Mol Ther 15:492–500CrossRef
Metadaten
Titel
Priapism in a Fabry disease mouse model is associated with upregulated penile nNOS and eNOS expression
verfasst von
Xing-Li Meng
Erland Arning
Mary Wight-Carter
Taniqua S. Day
Siamak Jabbarzadeh-Tabrizi
Shuyuan Chen
Robin J. Ziegler
Teodoro Bottiglieri
Jay W. Schneider
Seng H. Cheng
Raphael Schiffmann
Jin-Song Shen
Publikationsdatum
06.11.2017
Verlag
Springer Netherlands
Erschienen in
Journal of Inherited Metabolic Disease / Ausgabe 2/2018
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-017-0107-6

Weitere Artikel der Ausgabe 2/2018

Journal of Inherited Metabolic Disease 2/2018 Zur Ausgabe

Highlights

News and views

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.